

brought to you by [www.thebacteriophages.org](http://www.thebacteriophages.org) and [www.phage.org](http://www.phage.org)

## References

1. **Alisky, J., K. Iczkowski, A. Rapoport, and N. Troitsky.** 1998. Bacteriophages show promise as antimicrobial agents. *J. Infection* **16**: 5-15.
2. **Altschul, S. F., G. Gish, W. Miller, E. W. Myers, and D. J. Lipman.** 1990. Basic local alignment search tool. *J. Mol. Biol.* **215**: 403–410.
3. **Appelmans, R.** 1921. Le bacteriophage dans l'organisme. *Comp. Rend. Soc. de biol. (Paris)* **85**: 722-724.
4. **Arap, W., M. G. Kolonin, M. Trepel, et al.** 2002. Steps toward mapping the human vasculature by phage display. *Nat. Med.* **8**: 121-127.
5. **Asheshov, I. N., J. Wilson, and W. W. C Topley.** 1937. The effect of an anti-vi bacteriophage on typhoid infection in mice. *The Lancet* 319-320.
6. **Atanasiu, C., O. Byron, H. McMiken, S. S. Sturrock, and D. T. F. Dryden.** 2001. Characterisation of the structure of ocr, the gene 0.3 protein of bacteriophage T7. *Nucl. Acids. Res.* **29**: 3059-3068.

7. **Barrow, P., M. Lovell, and A. Berchieri.** 1998. Use of lytic bacteriophage for control of experimental *E. coli* septicemia and meningitis in chickens and calves. *Clin. Diag. Lab. Immunol.* **5**: 294-298.
  
8. **Bartlett, J. G.** 2002. Antibiotic-associated diarrhea. *N. Engl. J. Med.* **346**: 334-339.
  
9. **Bernhardt, T. G., I.-N. Wang, D. K. Struck, and R. Young.** 2001. A protein antibiotic in the phage Qb virion: diversity in lysis targets. *Science* **292**: 2326-2329.
  
10. **Biswas, B., S. Adhya, P. Washart, B. Paul, A. N. Trostel, B. Powell, R. Carlton, and C. R. Merrill.** 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant *Enterococcus faecium*. *Infect. Immun.* **70**: 204-210.
  
11. **Boyd, E. F., B. M. Davis, and B. Hochhut.** 2001. Bacteriophage-bacteriophage interactions in the evolution of pathogenic bacteria. *Trends Microbiol.* **9**: 137-144.
  
12. **Broxmeyer, L., D. Sosnowska, E. Miltner, O. Chacón, D. Wagner, J. McGarvey, R. G. Barletta, and L. E. Bermudez.** 2002. Killing of *Mycobacterium avium* and *Mycobacterium tuberculosis* by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. *J. Infect. Dis.* **186**: 1155-1160.

13. **Brussow, H. and R. W. Hendrix.** 2002. Phage genomics: small is beautiful. *Cell* **108**: 13–16.
  
14. **Calalb, G.** 1925. Action de la bile sur bacteriophage et importance de cette action. *Compt. Rend. Soc. De Boil. (Paris)* **92**: 1442-1443.
  
15. **Carriere, C., P. F. Riska, O. Zimhoney, J. Kriakov, S. Bardarov, J. Burns, J. Chan, and W. R. Jacobs.** 1997. Conditionally replicating luciferase reporter phages: improved sensitivity for rapid detection and assessment of drug susceptibility of *Mycobacterium tuberculosis*. *J. Clin. Microbiol.* **35**: 3232-3239.
  
16. **Ching, Y-C., S. D. Davis, and R. J. Wedgwood.** 1966. Antibody studies in hypogammaglobulinemia. *J. Clin. Invest.* **45**: 1593-1600.
  
17. **Colvin, M. G.** 1932. Behavior of bacteriophage in body fluids and in exudates. *J. Infect. Dis.* **51**: 527-541.
  
18. **Danese, P. N., L. A. Pratt, S. L. Dove, and R. Kolter.** 2000. The outer membrane protein, antigen 43, mediates cell-to-cell interactions within *Escherichia coli* biofilms. *Mol. Microbiol.* **37**: 424- 432.
  
19. **d'Herelle, F.** 1926. *The Bacteriophage and its Behavior.* Williams & Wilkins, Baltimore, MD. pp. 490-497, 540-549, 540 and 541.

20. **d'Herelle, F., and M. L. Rakieta.** 1935. The adaptation of a staphylococcus bacteriophage to an artificially produced anti-bacteriophagic serum. *J. Immunol.* **28**: 413-423.

21. **Doerfler, W., G. Orend, R. Schubbert, K. Fichtler, H. Heller, P. Wilgenbus, and J. Schroer.** 1995. On the insertion of foreign DNA into mammalian genomes: mechanism and consequences. *Gene* **157**: 241-245.

22. **Dubos, R. J., J. H. Straus, and C. Pierce.** 1943. The multiplication of bacteriophage *in vivo* and its protective effects against experimental infection with *Shigella dysenteria*. *J. Exp. Med.* **20**: 161-168.

23. **Eaton, M. D. and S. Bayne-Jones.** 1934. Bacteriophage therapy. *JAMA* **103**: 1769-1776, 1847-1853 and 1934-1939.

24. **Evans, A. C.** 1933. Inactivation of antistreptococcus bacteriophage by animal fluids. *Public Health Reports* **48**: 411-426.

25. **Flaherty, J. E., J. B. Jones, B. K. Harbaugh, G. C. Somodi, and L. E. Jackson.** 2000. Control of bacterial spot on tomato in the greenhouse and field with H-mutant bacteriophages. *Hortscience* **35**: 882-884.

**26. Flaherty, J. E., B. K. Harbaugh, J. B. Jones, G. C. Somodi, and L. E. Jackson.**

2001. H-mutant bacteriophages as a potential biocontrol of bacterial blight of geraniums.

Hortscience **36**: 90-100.

**27. Francis, K. P., J. Yu. C. Bellinger-Kawahara, D. Joh, M. J. Hawkinson, G. Xiao,**

**T. F. Purchio, M. G. Caparon, M. Lipsitch, and P. R. Contag.** 2001. Visualizing

*Pneumococcal* infections in the lungs of live mice using bioluminescent *Streptococcus*

*pneumoniae* transformed with a novel gram-positive lux transposon. Infect. Immun. **69**:

3350–3358.

**28. Gabig, M., A. Herman-Antosiewicz, M. Kwiatkowska, M. Los, M. S. Thomas,**

**and G. Wegrzyn.** 2002. The cell surface protein Ag43 facilitates phage infection of

*Escherichia coli* in the presence of bile salts and carbohydrates. Microbiology **148**: 1533-

1542.

**29. Gaeng, S., S. Scherer, H. Neve, and M. J. Loessner.** 2000. Gene cloning and

expression and secretion of *Listeria monocytogenes* bacteriophage-lytic enzymes

*Lactococcus lactis*. Appl. Environ. Microbiol. **66**: 2951-2958.

**30. Geier, M. R., M. E. Trigg, and C. R. Merrill.** 1973. The fate of bacteriophage

lambda in non-immune germfree mice. Nature **246**: 221-223.

31. **Hamels, S., J. L. Gala, S. Dufour, P. Vannuffel, N. Zammateo, and J. Remacle.**

2001. Consensus PCR and microarray for diagnosis of the genus *Staphylococcus* species and methicillin resistance. *Biotechniques* **31**: 1364-1366, 1368, 1370-1372.

32. **Ho, K.** 2001. Bacteriophage therapy for bacterial infections. *Perspect. Biol. Med.* **44**: 1-16.

33. **Hollon, T.** 2002. Impossible vaccine tames *Staphylococcus aureus*. *The Scientist* **16**: 24-28.

34. **Horst, J., F. Kluge, K. Beyreuther, and W. Gerok.** 1975. Gene transfer to human cells: transducing phage Lambda plac gene expression in GM1-gangliosidosis fibroblasts. *Proc. Natl. Acad. Sci. USA* **72**: 3531-3535.

35. **Inchley, C. J.** 1969. The activity of mouse kupffer cells following intravenous injection of T4 bacteriophage. *Clin. Exp. Immunol.* **5**: 173-187.

36. **Jenne, S., K. Brepoels, D. Collen, and L. Jespers.** 1998. High resolution mapping of the B cell epitopes of staphylokinase in humans using negative selection of a phage-displayed antigen library. *J. Immunol.* **161**: 3161-3168.

37. **Kilman, S.** 2002. FDA restricts antibiotic use in livestock to protect people. *The Wall Street Journal*. September 12, page D3.

38. **Knight, J.** 2002. Superbugs reveal chink in armour. *Nature* **417**: 477.
  
39. **Larkum, N. W.** 1932. Bacteriophage in clinical medicine. *J. Lab. Clin. Med.* **17**: 675-680.
  
40. **Larocca, D., M. A. Burg, K. Jensen-Pergakes, E. P. Ravey, A. M. Gonzalez, and A. Baird.** 2002. Evolving phage vectors for cell targeted gene delivery. *Curr. Pharm. Biotech.* **3**: 45-57.
  
41. **Lay, Jr., J. O.** 2001. Maldi-T of mass spectrometry of bacteria. *Mass Spec. Rvw.* **20**: 172-194.
  
42. **Lederberg, J.** 1996. Smaller fleas...ad infinitum: therapeutic bacteriophage redux. *Proc. Natl. Acad. Sci. USA* **93**: 3167-3168.
  
43. **Levin, B. R., and J. J. Bull.** 1996. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. *Am. Nat.* **147**: 881-898.
  
44. **Liu, M., R. Deora, S. R. Doulatov, M. Gingery, F. A. Eiserling, A. Preston, D. J. Maskell, R. W. Simons, P. A. Cotter, J. Parkhill, and J. F. Miller.** 2002. Reverse

transcriptase-mediated tropism switching in *Bordetella* bacteriophage. *Science* **295**: 2091- 2094.

45. **Loessner, M. J., C. E. D. Rees, A. B. Steward, and S. Scherer.** 1996. Construction of luciferase reporter bacteriophage A511::*luxAB* for rapid and sensitive detection of viable *Listeria* cells. *Appl. Environ. Microbiol.* **62**: 1133-1140.

46. **Medzhitov, R., and C. Janeway.** 2000. Innate immunity. *N. Engl. J. Med.* **343**: 338-344.

47. **Merril, C. R., M. R. Geier, and J. C. Petriccioni.** 1971. Bacterial virus gene expression in human cells. *Nature* **233**: 398-400.

48. **Merril, C. R., T. B. Friedman, A. Attallah, M. R. Geier, K. Krell, and R. Yarkin.** 1972. Isolation of bacteriophages from commercial sera. *In Vitro* **8**: 91-93.

49. **Merril, C. R.** 1975. Phage in human vaccines. *Science* **188**: 8.

50. **Merril, C. R., B. Biswas, R. Carlton, N. C. Jensen, G. J. Creed, S. Zullo, and A. Adhya.** 1996. Long-circulating bacteriophage as antibacterial agents. *Proc. Natl. Acad. Sci. USA* **93**: 3188-3192.



51. **Moffatt, B. A. and F. W. Studier.** 1988. Entry of bacteriophage T7 DNA into the cell and escape from host restriction. *J. Bacteriol.* **170**: 2095-2105.
52. **Naidu, B. P. B. and C. R. Avari.** 1932. Bacteriophage in the treatment of plague. *Ind. J. Med. Res.* **19**: 737-748.
53. **Nakai, T. and S. C. Park.** 2002. Bacteriophage therapy for infectious diseases in aquiculture. *Res. Microbiol.* **153**: 13-18.
54. **Nelson, D., L. Loomis, and V. Fischetti.** 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. *Proc. Natl. Acad. Sci. USA* **98**: 4107-4112.
55. **Nungester, W. J. and R. M. Watrous.** 1934. Accumulation of bacteriophage in spleen and liver following its intravenous inoculation. *Proc. Soc. Exper. Biol. Med.* **31**: 901-905.
56. **Ochs, H. D., S. D. Davis, and R. J. Wedgwood.** 1971. Immunologic responses to bacteriophage  $\phi$ X 174 in immunodeficiency diseases. *J. Clin. Invest.* **50**: 2559-2568.
57. **Ochs, H. D., S. Nonoyama, Q. Zhu, M. Farrington, and R. J. Wedgwood.** 1993. Regulation of antibody responses: the role of complement and adhesion molecules. *Clin. Immunol. Immunopathol.* 3 Pt 2 S33-40.

58. **Payne, R. J. H., and V. A. A. Jansen.** 2001. Understanding bacteriophage therapy in a density-dependent kinetic process. *J. Theor. Biol.* **208**: 37-48.

59. **Ramesh, V., J. A. Fralick, and R. D. Rolfe.** 1999. Prevention of *Clostridium difficile*-induced ileocectitis with bacteriophage. *Anaerobe* **5**: 69-78.

60. **Randall-Hazelbauer, L. and M. Schwartz.** 1973. Isolation of the bacteriophage lambda receptor from *Escherichia coli*. *J. Bacteriol.* **116**: 1436-1446.

61. **Sandmeier, H.** 1994. Acquisition and rearrangement of sequence motifs in the evolution of bacteriophage tail fibres. *Mol. Microbiol.* **12**: 343-350.

62. **Scholl, D., S. Rogers, S. Adhya, and C. Merrill.** 2001. Bacteriophage K1-5 encodes two different tail fiber proteins allowing it to infect and replicate on both K1 and K5 strains of *E. coli*. *J. Virol.* **75**: 2509-2515.

63. **Scholl, D., S. Adhya, and C. R. Merrill.** 2002. Bacteriophage SP6 is closely related to phages K1-5, K5 and K1E but encodes a tail protein very similar to that of the distantly related P22. *J. Bacteriol.* **184**: 2833-2836.

64. **Schubbert, R., D. Renz, B. Schmitz, and W. Doerfler.** 1997. Foreign (M13) DNA ingested by mice reaches peripheral leukocytes, spleen, and liver via the intestinal wall

mucosa and can be covalently linked to mouse DNA. Proc. Natl. Acad. Sci. USA **94**: 961–966.

65. **Schubbert, R., U. Hohlweg, D. Renz, and W. Doerfler.** 1998. On the fate of orally ingested foreign DNA in mice: chromosomal association and placental transmission to the fetus. Mol. Gen. Genet. **259**: 569-576.

66. **Schuch, R., D. Nelson, and V. A. Fischetti.** 2002. A bacteriolytic agent that detects and kills *Bacillus anthracis*. Nature **418**: 884-889.

67. **Smith, H. W., and M. B. Huggins.** 1982. Successful treatment of experimental *E. coli* infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. **128**: 307-318.

68. **Smith, H. W., M. B. Huggins, and K. M. Shaw.** 1987. The control of experimental *E. coli* diarrhea in calves by means of bacteriophages. J. Gen. Microbiol. **133**: 1111-1126.

69. **Smith, H. W., M. B. Huggins, and K. M. Shaw.** 1987. Factors influencing the survival and multiplication of bacteriophages in calves and their environments. J. Gen. Microbiol. **133**: 1127-1135.

70. **Sokoloff, A. V., I. Bock, G. Zhang, M. G. Sebestyen, and J. A. Wolff.** 2000. The interactions of peptides with the innate immune system studied with use of T7 phage peptide display. *Mol. Ther.* **2**: 131-139.

71. **Soothill, J. S.** 1992. Treatment of experimental infections of mice with bacteriophages. *J. Med. Microbiol.* **37**: 258-262.

72. **Soothill, J.S.** 1994. Bacteriophage prevents destruction of skin grafts by *Pseudomonas aeruginosa*. *Burns* **20**: 209-211.

73. **Stent, G. S.** 1963. Molecular biology of bacterial viruses. W. H. Freedman and Co., San Francisco, CA pp 8.

74. **Straub, M. E. and M. Applebaum.** 1933. Studies on commercial bacteriophage products. *JAMA* **100**: 110-113.

75. **Summers, W. C.** 2001. Bacteriophage therapy. *Ann. Rev. Microbiol.* **55**: 437-451.

76. **Trepel, M., W. Arap, and R. Pasqualini.** 2002. In vivo phage display and vascular heterogeneity: implications for targeted medicine. *Curr. Opin. Chem. Biol.* **6**: 399-404.

77. **Twort, F. W.** 1915. An investigation on the nature of ultra-microscopic viruses. *Lancet* **2**: 1241-1243.

78. **Uhr, J. W., M. S. Finkelstein, and J. B. Baumann.** 1962. Antibody formation: III. the primary and secondary antibody response to bacteriophage  $\phi$ X 174 in guinea pigs. *J. Exp. Med.* **115**: 655-670.

79. **Van Baar, B. L. M.** 2000. Characterisation of bacteria by matrix-assisted laser desorption/ionisation and electrospray mass spectrometry. *FEMS Microbiol. Rvw.* **24**: 193-219.

80. **Van Helvoort, T.** 1992. Bacteriological and physiological research styles in the early controversy on the nature of the bacteriophage phenomenon. *Med. History* **36**: 234-270.

81. **Wagner, P. L. and M. K. Waldor.** 2002. Bacteriophage control of bacterial virulence. *Infect. Immun.* **70**: 3985-3993.